Abbott Laboratories has received FDA clearance for its new Libre Duo 10 Day wearable device, the first in the US to continuously monitor both glucose and ketone levels, potentially transforming diabetes management and risk detection.
Abbott Laboratories has won US Food and Drug Administration clearance for a new wearable that combines continuous glucose and ketone monitoring, a step that could widen the company’s role in diabetes care. The agency said the Libre Duo 10 Day is the first device in the US able to track both measures continuously, giving patients and clinicians real-time data that may help spot early signs of diabetic ketoacidosis, a dangerous diabetes complication.
The device is authorised for people with diabetes aged two and older, according to the FDA. Abbott says the system is designed to sit alongside its existing FreeStyle Libre business and could eventually connect with insulin pump platforms in the US, extending the company’s push into digitally linked chronic disease management.
For Abbott, the decision adds another product to a diabetes portfolio that has become central to its medical technology strategy. The company has been leaning on higher-margin devices and software to support growth, and the new sensor may strengthen its pitch to hospitals, doctors and payers looking for more integrated monitoring tools.
The launch also highlights a competitive race in continuous monitoring, where rivals such as Dexcom and Medtronic are trying to deepen their own device ecosystems. Abbott will still have to prove that the added ketone data justifies any pricing premium and that the product can win reimbursement and adoption in a crowded market, especially as more connected diabetes systems reach patients.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
